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ABSTRACT AnnexinA5(AnxA5)hasahighafﬁnityforphosphatidylserine.Theproteiniswidelyusedtodetectapoptoticcells
becausephosphatidylserine,aphospholipidthatisnormallypresentintheinnerleaﬂetsofcytoplasmicmembranes,becomes
translocatedtotheouterleaﬂetsduringprogrammedcelldeath.HerewereportthenovelobservationthatAnxA5bindsto
Gram-negativebacteriaviathelipidAdomainoflipopolysaccharide(LPS).BindingofAnxA5tobacteriawasmeasuredquanti-
tatively,conﬁrmedbyﬂuorescencemicroscopy,andfoundtobeinhibitedbyantibodiesagainstlipidA.AnxA5alsoboundto
puriﬁeddot-blottedLPSandlipidA.Throughellipsometry,wefoundthatthebindingofAnxA5topuriﬁedLPSwascalcium
dependentandrapidandshowedahighafﬁnity—characteristicssimilartothoseofAnxA5bindingtophosphatidylserine.Ini-
tialfunctionalstudiesindicatedthatAnxA5canaffectLPSactivities.AnxA5inhibitedLPS-mediatedgelationinthe Limulus
amebocytelysateassay.IncubationofLPSwiththeproteinreducedthequantityoftumornecrosisfactoralpha(TNF-)released
by cultured monocytes compared to that released upon incubation with LPS alone. Initial in vivo experiments indicated that
injectionofmicewithLPSpreincubatedwithAnxA5producedserumTNF-levelslowerthanthoseseenafterinjectionofLPS
alone.ThesedatademonstratethatAnxA5bindstoLPSandopenpathstoinvestigationofthepotentialbiologicalandtherapeu-
ticimplicationsofthisinteraction.
IMPORTANCE AnxA5ishighlyexpressedincellsthathaveabarrierfunction—including,amongothers,vascularendothelium,
placentaltrophoblasts,andepithelialcellsliningbileducts,renaltubules,mammaryducts,andnasalepithelium.Theprotein
hasbeenwellcharacterizedforitsbindingtophospholipidbilayersthatcontainphosphatidylserine.Thisreportofapreviously
unrecognizedactivityofAnxA5opensthedoortoinvestigationofthepossibilitythatthisbindingmayhavebiologicalandther-
apeuticramiﬁcations.Inviewofthetissueexpressionoftheprotein,thepresentresultssuggestthepossibilitythatAnxA5plays
aroleinmodulatingthehostdefenseagainstlipopolysaccharideattheseanatomicsites,wherecellsmayinterfacewithmicroor-
ganisms.TheseresultsalsoraisetheintriguingpossibilitythatAnxA5oranalogousproteinsorpeptidescouldprovidenovel
approachestoaddressingthedifﬁcultclinicalproblemofGram-negativesepsis.
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A
nnexinA5(AnxA5;aproteinthatisgenerallybetterknownby
its former name, annexin V) binds to phospholipids in a
calcium-dependent manner and forms two-dimensional crystal
lattices over the phospholipid bilayers that express phosphatidyl-
serine (1). AnxA5 has become a widely used marker for detecting
apoptotic cells because phosphatidylserine, which is normally lo-
calized within the internal leaﬂets of cytoplasmic membranes, is
expressedonthecellsurfaceduringprogrammedcelldeath(2–4).
ThebiologicalfunctionofAnxA5hasnotbeenestablished.The
protein is highly expressed by cells that serve a barrier function,
including vascular endothelium cells and placental trophoblasts
(for a review, see reference 5). A main focus has been on the pro-
tein’s anticoagulant properties, which result from its high afﬁnity
foranionicphospholipids(6,7).Thereissigniﬁcantevidencethat
the protein serves an antithrombotic function on vascular endo-
thelial cells and placental trophoblasts since autoantibody-
mediated deﬁciencies are associated with vascular atherothrom-
bosis (8, 9) and with recurrent pregnancy losses (10–12). In
addition,AnxA5hasbeenshowntomodulatetissuefactorexpres-
sion (13), to promote endocytosis (14), and to participate in cell
protection from engulfment by phagocytosis (15). However, the
fact that the protein is highly expressed by cells that have a barrier
function but do not play any role in blood coagulation—such as
biliary,pancreatic,salivary,andrenalductularepithelialcells(16)
and mammary epithelium cells (17)—suggests that it may serve
other functions.
Lipopolysaccharide (LPS), a complex lipoglycan that is ex-
pressed in the outer membrane of Gram-negative bacteria, is the
key molecule responsible for the clinical manifestations of Gram-
negative sepsis and septic shock. The lipid A domain, which is
mainly responsible for the endotoxin effect of LPS (18), is highly
conserved across bacterial species. LPS activates the host defense
response through the binding of the lipid A domain to a receptor
complex that includes Toll-like receptor 4, CD14, and MD2 (19)
on monocytes and other cell types which, in turn, triggers the
innate immune response which is characterized by secretion of
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(TNF-).
Inviewoftheinterestingevidencethatsuggestsapotentialrole
forbacteriaintriggeringdisordersthathaveanautoimmunecom-
ponent—e.g., the antiphospholipid syndrome (20) and heparin-
induced thrombocytopenia with thrombosis (21)—we wondered
whether bacteria might also bind AnxA5. To our surprise, we
found this to be the case for Gram-negative bacteria but not
Gram-positivebacteria.WefoundthatAnxA5bindstothelipidA
portion of LPS and intact LPS. Furthermore, we demonstrated
that,similartothebindingofAnxA5tophospholipid,thebinding
of AnxA5 to LPS is rapid, shows a high afﬁnity, and is calcium
dependent. Finally, in initial studies to evaluate the possibility of
functional implications, we showed that AnxA5 binding can also
reduce endotoxin effects of LPS.
RESULTS
AnxA5 binding to bacteria. Pure cultures of bacteria were
screened for AnxA5 binding activity using a standard
ﬂuorescence-tagged AnxA5 protein that is used to detect apopto-
tic cells. We found that Gram-negative bacteria, including Pseu-
domonas aeruginosa, Shewanella putrefaciens, and Haemophilus
inﬂuenzae,boundtheproteininthepresenceofcalciumbutnotin
its absence, while there was no appreciable binding to Gram-
positive bacteria, including Enterococcus faecalis, Streptococcus
pyogenes, and Streptococcus agalactiae (Fig. 1A).
These quantitative results were conﬁrmed by ﬂuorescence mi-
croscopy of the bacteria (Fig. 1B, parts a, b, and c). The apparent
speciﬁcityofthebindingtoGram-negativebacteriasuggestedthat
the binding site for AnxA5 might be LPS. If that were the case, we
suspected that binding might occur via the highly conserved lipid
A domain of LPS because that domain shows some of the struc-
tural features of anionic phospholipids (22, 23). Those ideas were
supported by our ﬁnding that polyclonal antibody against lipid A
blockedthebindingofAnxA5toGram-negativebacteria(Fig.1B,
partsd,e,andf).Inaddition,instudiesdescribedbelow,wedem-
onstrated that AnxA5 binds directly to puriﬁed LPS and to puri-
ﬁed lipid A.
AnxA5 binding to LPS. We used ellipsometry, an established
precise and quantitative method that has been useful for measur-
ing the adsorption of proteins to phospholipids (6, 24, 25), to
monitor the adsorption of AnxA5 to LPS that had been mounted
on reﬂective silicon slides. AnxA5 bound to LPS almost immedi-
ately, with maximal binding achieved within 5 min (Fig. 2A). The
resultsoftheellipsometryexperimentsshowedthatAnxA5bound
LPS in the presence of ionized calcium but not in its absence
(Fig. 2A). In addition, after binding to LPS, AnxA5 was rapidly
dissociatedwhenthecalciumchelatorEDTAwasadded(Fig.2A).
Binding isotherms conﬁrmed the binding to have a high afﬁnity
with an equilibrium constant, KD, for AnxA5-LPS interaction of
19.4  4.8 nM (P  0.007) (Fig. 2B).
Experiments with puriﬁed LPS dot blotted onto membranes
conﬁrmed that soluble AnxA5 bound to LPS in the presence of
ionized calcium but not in its absence (Fig. 3A). Furthermore, as
withintactGram-negativebacteria,preincubationofpuriﬁedLPS
with antibody against lipid A blocked the binding of AnxA5
(Fig. 3B).
Effects of AnxA5 on LPS endotoxin activity. We performed
initial proof-of-principle studies to evaluate whether this binding
might modulate LPS activity. We investigated the effect of AnxA5
binding with the standard Limulus amebocyte lysate (LAL) assay
(26), with measurements of the release of TNF- (27, 28) from
cultured macrophages stimulated with LPS, and with assays of
serum TNF- levels in mice that were intravenously infused with
LPS. AnxA5 neutralized LPS activity in the LAL assay; gel forma-
tion induced by 0.05 ng/ml LPS was completely inhibited by
AnxA5 at 10 ng/ml (Table 1). Similarly, AnxA5 reduced the mac-
rophage response to LPS; exposure of cells to 1 ng/ml LPS in the
absence of AnxA5 resulted in an 8-fold-increased level of TNF-
intheculturemedium,whereaspreincubationofLPSwithAnxA5
at 0.04 g/ml and 0.2 g/ml signiﬁcantly reduced this effect in a
dose-dependent manner (Fig. 4A).
FIG 1 AnxA5 binding to bacteria. (A) Measurements of AnxA5 binding to
Gram-negative and -positive bacteria. Bacteria were incubated with OG-
AnxA5 in HBS containing 5 mM CaCl2. The bound AnxA5 was dissociated
from bacteria with EDTA and measured. The Gram-negative bacteria had
markedly higher levels of bound AnxA5 than the Gram-positive bacteria
(mean ﬂuorescence intensity  standard deviation, 114.9  7.9 versus 7.7 
1.9). (B) Fluorescence microscopic conﬁrmation of OG-AnxA5 binding to
Gram-negative bacteria. Bacteria incubated with OG-AnxA5 were stained
strongly with Oregon Green (a, c, and e); bacteria that were pretreated with
antibody against the lipid A core of LPS prior to incubation with OG-AnxA5
had markedly reduced Oregon Green staining (b, d, and f) (1,000 magniﬁ-
cation under oil immersion).
Rand et al.
2
® mbio.asm.org March/April 2012 Volume 3 Issue 2 e00292-11AnxA5 also reduced the endotoxin effect of LPS in vivo. Mice
thatwereintravenouslyinfusedwithLPS(1g/kgofbodyweight)
that was preincubated with AnxA5 (100 g/kg of body weight)
had signiﬁcantly lower serum TNF- concentrations than mice
infused with LPS alone (Fig. 4B). The TNF- concentrations of
themiceinfusedwithLPSplusAnxA5wassimilartomicetreated
with normal saline or with AnxA5 alone (Fig. 4B).
To summarize, we found that AnxA5 binds to Gram-negative
bacteria via the lipid A portion of LPS and reverses the molecule’s
endotoxinactivityinvitroandinvivo.BindingofAnxA5toGram-
negative bacteria was evidenced by measurements of the binding
ofﬂuorescence-taggedAnxA5tobacteriaandbyﬂuorescencemi-
croscopic imaging of bacteria. AnxA5 binding was conﬁrmed to
occurviaLPSthroughligand-bindingstudiesonbacterialextracts
andwithpuriﬁedLPS.Weshowedthatthisbindingoccursviathe
lipidAcoreofLPS,whichisresponsiblefortheendotoxinactivity
bydemonstratingthatantibodyagainstlipidAblocksthebinding
ofAnxA5tobacteriaandalsobydemonstratingthatAnxA5binds
to puriﬁed lipid A. Through ellipsometric measurements of the
binding of AnxA5 to LPS, we found that binding occurs rapidly,
demonstrates a high afﬁnity, and exhibits calcium dependence.
We then found that the binding of AnxA5 to LPS affects the en-
dotoxin activity of LPS as reﬂected by the neutralization of gela-
tion in the LAL assay, the reduction of the release of TNF- by
cultured macrophages. Finally, preincubation with AnxA5 also
reduced the endotoxin effect of LPS in vivo, as evidenced by the
reductionofTNF-levelsintheserumofmiceinjectedwithLPS.
DISCUSSION
Despite major advances in the understanding of its pathophysiol-
ogy, septic shock has had a growing impact on morbidity and
mortality and has been relatively resistant to newer therapeutic
approaches—forarecentconcisereview,seereference29.Ascited
inthatreview,hospitalmortalityratesforsepticshock,wheredata
are available from international registries, range from 30% to
morethan50%(29).Therehasbeenconsiderableinterestinchar-
acterizing LPS-binding proteins with an eye toward understand-
ing how these might modulate their biological effects and the ad-
FIG 2 Ellipsometry studies of AnxA5 binding to LPS. (A) Ellipsometry trac-
ing of AnxA5 binding to puriﬁed LPS. In the presence of calcium, the net
binding of the protein to LPS was rapid, reaching a maximum level within
5 min; addition of EDTA immediately dissociated the bound AnxA5 from the
LPS. In the absence of calcium, virtually no binding of AnxA5 to LPS was
observed. (B) AnxA5 binding isotherm showing the maximum binding den-
sities (Bmax) and KD values for the AnxA5-LPS interaction.
FIG 3 Immunoblot studies of AnxA5 binding to extracts of Gram-negative
bacteria. (A) Dot-immunoblot study of AnxA5 binding to LPS. Puriﬁed LPS,
AnxA5(aspositivecontrol),andbovineserumalbumin(asanegativecontrol)
were applied to immunoblot PVDF membranes; the membranes were incu-
batedwithbuffercontainingAnxA5,followedbyantibodyagainstAnxA5.The
blots that were exposed to AnxA5 in the presence of 5 mM CaCl2 showed
dose-dependentAnxA5bindingtoLPS.TheblotincubatedwithaddedAnxA5
in buffer without calcium showed no staining for bound AnxA5. (B) Dot-
immunoblot study of effects of antibody against lipid A on AnxA5 binding.
Exposure to anti-lipid A antibody prior to incubation with AnxA5 markedly
inhibited the binding of AnxA5.
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Gram-negative sepsis (for a recent review, see reference 30). A
number of serum proteins have been shown to bind to LPS with
divergent effects (31). It was previously shown that two other an-
nexins—annexin A1 and annexin A2—can bind to puriﬁed lipid
A but that those annexins do not bind to LPS itself (32).
The present data showing high-afﬁnity binding of AnxA5 to
LPS on Gram-negative bacteria and the reversal of endotoxin ac-
tivity raise the possibility that the protein plays a role in the host
defense against the LPS-induced provocation of the innate (non-
adaptive)immuneresponsewithitsdownstreamclinicalsequelae
of Gram-negative endotoxemia by neutralizing LPS in vivo. The
fact that, as mentioned above, AnxA5 is highly expressed by cell
typesthathaveabarrierfunction,includingvascularendothelium
cells(33),placentaltrophoblasts(34),biliary,pancreatic,salivary,
and renal ductular epithelial cells (16), and mammary epithelium
cells(17),amongothers,leadsustospeculatethattheproteinmay
be concentrated in anatomic locations where it may serve to pro-
tect against attack by LPS. Of course, this concept of a biological
role for AnxA5 in host defense requires proof by rigorous direct
experimentation.
It is also possible that the present ﬁndings point to new ap-
proaches for addressing Gram-negative sepsis. In view of the dis-
appointments with other candidate LPS inhibitors, we speculate
that AnxA5 may be a good prophylactic agent against Gram-
negativesepsisorthatitmaybeeffectiveinsituationswherethere
may be chronic exposure to LPS, such as ventilator-associated
pneumonia.
The high afﬁnity of AnxA5 for LPS and the evidence for its
reductionoftheglycolipid’sendotoxinactivitybothinvitroandin
vivo raise the interesting potential that supplementation with
AnxA5 itself, or treatments with modiﬁed forms of the protein or
analogous compounds, may provide novel targeted therapies for
this difﬁcult-to-treat condition.
MATERIAL AND METHODS
Reagents. LPS extracted from P. aeruginosa serotype 10, a diphosphoryl
form of lipid A prepared from the LPS of a rough strain of E. faecalis, and
AnxA5 puriﬁed from human placenta were purchased from Sigma-
Aldrich.TheLPSusedfortheellipsometrybindingstudiesandformouse
infusionstudieswaspuriﬁedbyphenolextraction.Tofurtherensurethat
AnxA5 was binding to LPS, we performed binding studies with LPS that
wastakenthroughasecondphenolextractionstepaspreviouslydescribed
(35). Goat anti-lipid A IgG was purchased from Meridian Life Science,
Inc. (Saco, ME). Oregon Green-conjugated AnxA5 (OG-AnxA5) was
from Molecular Probes, Inc. (Invitrogen Corp., Carlsbad, CA). Rabbit
anti-humanAnxA5IgGwasafﬁnitypuriﬁedaspreviouslydescribed(34).
P. aeruginosa (ATCC 27853), S. putrefaciens (ATCC 8071), H. inﬂuenzae
(ATCC49776),E.faecalis(ATCC25922),S.pyogenes(ATCC19615),and
S. agalactiae (ATCC 19615) were purchased from standard clinical labo-
ratory suppliers.
AnxA5 binding to bacteria. We measured AnxA5 binding using a
procedure that we previously described for determining AnxA5 binding
to phospholipid suspensions (36), with some modiﬁcations. Brieﬂy, ap-
proximately 6  108 bacteria each of P. aeruginosa, S. putrefaciens, H.
inﬂuenzae, E. faecalis, S. pyogenes, and S. agalactiae were incubated in
duplicate with OG-AnxA5 (1 g/ml) in HEPES-buffered saline (HBS;
0.01MHEPES,0.14MNaCl,pH7.5)containing5mMCaCl2(200l)for
2 h at room temperature. The bacteria were centrifuged at 15,000 g for
10minat25°C,supernatantswereremoved,andpelletswerewashedonce
in 1 ml of the calcium-containing buffer and recentrifuged. The pellets
TABLE 1 Effect of AnxA5 on LAL test
Treatment
Gel formation at AnxA5 concn (g/ml) of:
0 0.0001 0.001 0.01 0.1 1 5 10
AnxA5  0.05 ng/ml LPSa in HBS containing 5 mM CaCl2     
a LPS at 1 ng/ml  5 EU.
FIG 4 Effect of AnxA5 on LPS-induced production of TNF- in vitro and in
vivo.(A)Invitro,mousemacrophagestreatedwith1ng/mlLPSand0.2g/ml
AnxA5 produced signiﬁcantly less TNF- than did cells treated with 1 ng/ml
LPS alone and cells treated with a mixture of 1 ng/ml LPS and 0.04 ng/ml
AnxA5. (B) In vivo, mice intravenously infused with LPS (1 g/kg of body
weight)withAnxA5(100g/kgofbodyweight)hadsigniﬁcantlylowerserum
TNF- levels than mice infused with LPS alone; these levels were not signiﬁ-
cantly(N.S)differentfromthoseofmiceinfusedwithcontrolnormalsalineor
with AnxA5 alone.
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for 5 min to dissociate bound AnxA5. The supernatants were transferred
to a microtiter plate, and AnxA5 was measured with a SpectraMax M5e
microplatespectroﬂuorimeter(MolecularDevices,Sunnyvale,CA)using
an excitation wavelength of 485 nm and an emission wavelength of
535 nm.
Fluorescence microscopy studies. Binding of AnxA5 to Gram-
negative bacteria was conﬁrmed by ﬂuorescence microscopy. Approxi-
mately 3  107 to 5  107 bacteria were smeared onto superior adhesive
slides (Surgipath), air dried in a biological safety cabinet, rehydrated with
HBS,ﬁxedwith5%formalinfor4minatroomtemperature,andwashed
three times in HBS to remove the ﬁxative. The bacteria were then incu-
batedwithHBSaloneorHBScontaininganti-lipidAantibody(50g/ml)
for 1 h and washed three times in HBS. The bacteria were then incubated
with OG-AnxA5 (5 g/ml) in HBS containing 5 mM CaCl2 f o r1h ,
washed four times in calcium-containing buffer, and mounted with
mounting medium (Vector Laboratories, Inc.). The OG-AnxA5-treated
bacteria were observed using an Olympus U-SPT Bx60F-3 ﬂuorescence
microscope (Diagnostic Instruments, Inc.), and images were obtained at
room temperature with a digital camera (model 2.3.0; Diagnostic Instru-
ments,Inc.)andacomputer(DellDimension4500)forstoringimagesas
TIFF ﬁles. The ﬂuorochrome Oregon Green was imaged by excitation at
488nm,andtheimageswereviewedat1,000magniﬁcationwitha100
objective lens under oil immersion. All of the images were obtained and
processedinthesamemanner;theywereallobtainedasgrayscaleimages,
saved as TIFF ﬁles with Adobe Photoshop CS, and converted to RGB.
After deletion of blue and red channels, the background was adjusted to
black. There was no further processing of the images.
Ellipsometrystudies.BindingofAnxA5topuriﬁedLPSwasobserved
in real time using a thin-ﬁlm ellipsometer (Rudolph & Sons, Inc., Fair-
ﬁeld, NJ). LPS (1 mg/ml) was applied to a silicon slide in 1.25 mM CaCl2
aspreviouslydescribed(37),andtheadsorptionofLPSwasmonitoredby
ellipsometry.TheimmobilizedLPSlayerswereﬂushedwithHBScontain-
ing 5 mM CaCl2 or HBS alone, AnxA5 (2 g/ml) was added, and the
binding of the protein to the LPS layer was monitored by ellipsometry.
After protein adsorption had reached equilibrium, EDTA (ﬁnal concen-
tration, 10 mM) was added to dissociate LPS-bound AnxA5. Parallel ex-
periments were performed to determine nonspeciﬁc AnxA5 binding to
background controls in which AnxA5 was applied to a blank silicon slide
and protein binding was determined by ellipsometry. Net LPS-bound
AnxA5 was then calculated by subtracting the background control from
the LPS-bound AnxA5.
To determine the afﬁnity of AnxA5 for LPS, aliquots of AnxA5 were
added serially (up to 5 g/ml) in the calcium-containing buffer after the
bindingofeachprioraliquothadreachedequilibrium.Basedonthemea-
sured free AnxA5 and the total amount of AnxA5 added to the LPS layer,
traditional graphs plotting LPS-bound AnxA5 versus free AnxA5 were
generated and the Langmuir isotherm was ﬁtted to the binding data to
determine the KD and maximum binding capacity using SigmaPlot soft-
ware (SPSS, Chicago, IL).
Dot-immunoblotstudies.BindingofAnxA5topuriﬁedLPSandlipid
A was studied using a dot-immunoblot method as previously described
(38), with modiﬁcation. Brieﬂy, puriﬁed LPS was applied to polyvi-
nylidene diﬂuoride (PVDF) membrane and incubated for1hi naw e t
chamber. The blots were washed three times in HBS and incubated with
3%bovineserumalbuminfor1htoblocknonspeciﬁcbinding.Theblots
were then incubated with AnxA5 (2 g/ml) for 1 h, washed, and then
incubatedwithrabbitanti-AnxA5IgG(1g/ml),followedbyhorseradish
peroxidase-conjugated goat anti-rabbit antibody (Thermo Scientiﬁc, IL);
alloftheincubationsweredoneinHBScontaining5mMCaCl2.Theblots
were then incubated with an enhanced chemiluminescence substrate
(Thermo Scientiﬁc) for 5 min and scanned using a Kodak Image Station
4000R (Carestream Health, Inc.) to visualize the binding of AnxA5.
Parallel studies were performed to determine whether the binding of
AnxA5toLPSandlipidAmightbeinhibitedbyantibodyagainstlipidAin
which the blots were incubated with anti-lipid A IgG (50 g/ml; Sigma)
for1hpriortoincubationwithAnxA5.ThebindingofAnxA5toLPSand
lipid A was then detected as described as above.
LAL test. The effect of AnxA5 on the endotoxin effect of LPS was
investigated using the standard LAL test as previously reported (26), with
minormodiﬁcation.Brieﬂy,afteraddingvariousconcentrationsofLPSin
HBS(200l)containing5mMCaCl2tosingletestvials(STVs)ofPyrotell
(Associates of Cape Cod, Inc.), it was determined that a positive test was
obtained with 0.05 ng/ml LPS. Various concentrations of AnxA5 (0 to
10 g/ml) were then added to this concentration of LPS and mixed thor-
oughly,theSTVswereimmediatelyplacedinadryblockincubator(Ther-
molyneDri-bath;ThermoScientiﬁc)at37°Cfor602min,andafterthe
incubation period, gel formation in the STVs was inspected according to
the manufacturer’s instructions.
Effects of AnxA5 in vitro on LPS-induced TNF- production. Since
LPS is known to stimulate macrophages to produce TNF- (27, 28), we
studied whether in vitro the binding of AnxA5 to LPS might affect LPS-
inducedTNF-productionbyamousemacrophagecelllinenamedRAW
264.7 (American Type Culture Collection). Pilot experiments indicated
that treatment of RAW cells with 1 ng/ml LPS increased TNF- levels
8-foldoverthoseinbuffer-treatedRAWcells.WethereforeusedthisLPS
concentration for the studies described below.
RAW cells were seeded into the wells of a 96-well tissue culture plate
(Becton Dickinson Labware) at a density of 1  104/well in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) containing 10% fetal bovine serum
andantibiotics(Gibco),maintainedinanincubator(Isotemp;FisherSci-
entiﬁc)containing5%carbondioxideand95%humidiﬁedairat37°Cfor
18 h, washed three times, and cultured in serum-free DMEM for 1 h.
AnxA5 (0.02 g/ml and 0.4 g/ml, respectively) and LPS (1 ng/ml) were
added to serum-free DMEM and incubated at 37°C for another1hi na
rotatingincubator(Isotemp,FisherScientiﬁc).Thecellswerethentreated
with AnxA5-LPS-containing, serum-free DMEM (100 l/well) versus
serum-free DMEM that included 1 ng/ml LPS and control serum-free
DMEM containing buffer (HBS) without LPS or AnxA5 for 24 h. The
conditioned media were collected, and the levels of TNF- were deter-
mined using a mouse TNF- enzyme-linked immunosorbent assay
(ELISA) kit (eBioscience Inc., San Diego, CA) according to the manufac-
turer’s instructions.
Effects of AnxA5 on LPS-induced TNF- production in vivo. We
also investigated whether AnxA5 might alter the endotoxin effects of LPS
in vivo. All procedures were conducted in accordance with NIH regula-
tions concerning the use and care of experimental animals and approved
by the Albert Einstein College of Medicine animal use committee.
C57BL/6 mice were housed in the pathogen-free barrier facility at the
Albert Einstein College of Medicine. Mixtures of AnxA5 (20 g/ml) and
LPS(0.2g/ml)innormalsalinewereincubatedat37°Cforatleast1hon
a rotator prior to injection of the mice. Pilot experiments showed that
treatment of mice with 1 g/kg LPS raised serum TNF- levels 40-fold
above those of normal, saline-treated mice. We therefore used this LPS
concentration for the studies described below.
Eighteen C57BL/6 mice 9 to 10 weeks old were randomly divided into
3 groups (n  6; 3 male and 3 female). LPS (1 g/kg of body weight) plus
AnxA5 (100 g/kg of body weight), LPS alone (1 g/kg of body weight),
normal saline alone, or AnxA5 alone was injected intravenously at the
same volume. After 4 h, the mice were sacriﬁced and blood was collected
bycardiacpunctureunderanesthesia.TheconcentrationofTNF-inthe
serum was determined by ELISA as described above.
Statistical analyses Statistical analyses were performed using un-
pairedttestswithGraphPadInStat(GraphPadSoftware,SanDiego,CA).
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